Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market

Looking at the earnings posted by Merck & amp; Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration so too is Januvia. The main difference is how each company planned for life beyond their respective mega-blockbusters.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news